ATE513034T1 - Verfahren zur gewinnung immortalisierter antikörpersezernierender zellen - Google Patents

Verfahren zur gewinnung immortalisierter antikörpersezernierender zellen

Info

Publication number
ATE513034T1
ATE513034T1 AT06830666T AT06830666T ATE513034T1 AT E513034 T1 ATE513034 T1 AT E513034T1 AT 06830666 T AT06830666 T AT 06830666T AT 06830666 T AT06830666 T AT 06830666T AT E513034 T1 ATE513034 T1 AT E513034T1
Authority
AT
Austria
Prior art keywords
cells
methods
human
secrete
antibodies
Prior art date
Application number
AT06830666T
Other languages
English (en)
Inventor
Ada Funaro
Gianni Garotta
Marianne Murphy
Original Assignee
Ribovax Biotechnologies Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ribovax Biotechnologies Sa filed Critical Ribovax Biotechnologies Sa
Application granted granted Critical
Publication of ATE513034T1 publication Critical patent/ATE513034T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • General Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Virology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
AT06830666T 2005-12-16 2006-12-15 Verfahren zur gewinnung immortalisierter antikörpersezernierender zellen ATE513034T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP2005056871 2005-12-16
PCT/EP2006/069780 WO2007068758A1 (en) 2005-12-16 2006-12-15 Methods for obtaining immortalized antibody secreting cells

Publications (1)

Publication Number Publication Date
ATE513034T1 true ATE513034T1 (de) 2011-07-15

Family

ID=36685876

Family Applications (1)

Application Number Title Priority Date Filing Date
AT06830666T ATE513034T1 (de) 2005-12-16 2006-12-15 Verfahren zur gewinnung immortalisierter antikörpersezernierender zellen

Country Status (19)

Country Link
US (1) US8338172B2 (de)
EP (1) EP1974020B1 (de)
JP (2) JP5431730B2 (de)
KR (1) KR101508945B1 (de)
CN (1) CN101374944B (de)
AT (1) ATE513034T1 (de)
AU (1) AU2006325236B2 (de)
BR (1) BRPI0619908A2 (de)
CA (1) CA2633601C (de)
DK (1) DK1974020T3 (de)
EA (1) EA019505B1 (de)
ES (1) ES2367322T3 (de)
IL (1) IL192095A0 (de)
NO (1) NO20083160L (de)
NZ (1) NZ569816A (de)
PL (1) PL1974020T3 (de)
PT (1) PT1974020E (de)
WO (1) WO2007068758A1 (de)
ZA (2) ZA200806094B (de)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2398783A (en) 2003-02-26 2004-09-01 Antonio Lanzavecchia A method for producing immortalised human B memory lymphocytes
GB0700133D0 (en) 2007-01-04 2007-02-14 Humabs Llc Human cytomegalovirus neutralising antibodies and use thereof
US7947274B2 (en) 2007-01-04 2011-05-24 Humabs, LLC. Human cytomegalovirus neutralising antibodies and use thereof
US8202518B2 (en) 2007-07-04 2012-06-19 Ribovax Biotechnologies S.A. Antibodies against human cytomegalovirus (HCMV)
EP3293269A1 (de) * 2007-08-03 2018-03-14 MUSC Foundation For Research Development Menschliche monoklonale antikörper und verfahren zu ihrer herstellung
EP2190876A1 (de) * 2007-08-22 2010-06-02 Ribovax Biotechnologies SA Antikörper gegen das humane cytomegalie-virus (hcmv)
PT3009449T (pt) 2008-07-16 2018-09-28 Inst Res Biomedicine Anticorpos neutralizantes de citomegalovírus humano e utilização destes
US8703486B2 (en) 2008-09-23 2014-04-22 UNIVERSITé LAVAL Method for polyclonal immunoglobulin G production by human B cells
DK2464664T3 (da) 2009-08-13 2016-01-18 Crucell Holland Bv Antistoffer mod humant respiratorisk syncytialvirus (rsv) og fremgangsmåder til anvendelse deraf
WO2011062997A2 (en) 2009-11-17 2011-05-26 Musc Foundation For Research Development Human monoclonal antibodies to human nucleolin
EA201270662A1 (ru) 2009-12-23 2013-01-30 4-Антибоди Аг Связывающие элементы для человеческого цитамегаловируса
ES2434256T3 (es) * 2010-05-28 2013-12-16 F. Hoffmann-La Roche Ag Método de cultivo de células B individuales y producción de anticuerpos específicos
EP2591000B1 (de) 2010-07-09 2017-05-17 Janssen Vaccines & Prevention B.V. Antikörper gegen humanes respiratorisches syncytialvirus (rsv) und ihre verwendung
CN102839152A (zh) * 2011-06-20 2012-12-26 中国科学院上海生命科学研究院 一种快速高效获得抗原特异性b细胞的方法
WO2013000982A1 (en) 2011-06-27 2013-01-03 Vivalis Method for screening cells
US9757458B2 (en) * 2011-12-05 2017-09-12 Immunomedics, Inc. Crosslinking of CD22 by epratuzumab triggers BCR signaling and caspase-dependent apoptosis in hematopoietic cancer cells
EP2797952B1 (de) 2011-12-28 2019-02-27 ImmunoQure AG Verfahren zur bereitstellung von monoklonalen auto-antikörpern mit der gewünschten spezifität
US10131709B2 (en) 2011-12-28 2018-11-20 Immunoqure Ag Nucleic acid molecules encoding monoclonal antibodies specific for IL-22
US20140199319A1 (en) * 2012-12-14 2014-07-17 Abbvie, Inc. Methods for increasing the efficiency of hybridoma generation
AU2013372026B2 (en) * 2013-01-03 2018-11-08 Merck Patent Gmbh Method for producing secretable antibodies by expression in saccharomyces cerevisiae
WO2015001047A1 (en) 2013-07-03 2015-01-08 Immunoqure Ag Method of providing anti-human cytokine antibodies for pharmaceutical use
US10611800B2 (en) 2016-03-11 2020-04-07 Pfizer Inc. Human cytomegalovirus gB polypeptide
JP6916884B2 (ja) * 2017-01-02 2021-08-11 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ Ｂ細胞培養法
EP3573649A4 (de) * 2017-01-27 2020-12-30 The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc. Impfstoffzusammensetzungen aus herpesvirus-hüllprotein-kombinationen zur induktion einer immunreaktion
US11629172B2 (en) 2018-12-21 2023-04-18 Pfizer Inc. Human cytomegalovirus gB polypeptide
CN111647566A (zh) * 2019-07-10 2020-09-11 广州医科大学附属第一医院 一种高滴度eb病毒的制备方法、eb病毒永生化记忆性b细胞的方法与应用
US11857622B2 (en) 2020-06-21 2024-01-02 Pfizer Inc. Human cytomegalovirus GB polypeptide
US11661459B2 (en) 2020-12-03 2023-05-30 Century Therapeutics, Inc. Artificial cell death polypeptide for chimeric antigen receptor and uses thereof
TW202237827A (zh) 2020-12-03 2022-10-01 美商世紀治療股份有限公司 經基因工程改造之細胞及其用途
JP2024500847A (ja) 2020-12-18 2024-01-10 センチュリー セラピューティクス，インコーポレイテッド 適合可能な受容体特異性を有するキメラ抗原受容体システム
US20260002127A1 (en) * 2022-12-06 2026-01-01 Kitayama Labes Co., Ltd. Method for producing immortalized cell
CN117230258B (zh) * 2023-11-10 2024-04-09 苏州驾玉生物医药有限公司 一种提高灵敏度的培养扩增联合pcr的eb病毒检测方法
CN119285758B (zh) * 2024-10-31 2025-07-01 上海百英生物科技股份有限公司 一种基于b细胞永生化的单个b细胞抗体开发方法及其应用
CN120272432B (zh) * 2025-03-25 2025-12-26 佛山市妇幼保健院 一种脊髓性肌萎缩症质控品及其制备方法和应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4997764A (en) * 1987-04-23 1991-03-05 New York University Transformation of human B-lympocytes with Epstein Barr virus and c-myc containing vectors
ATE132907T1 (de) * 1989-09-19 1996-01-15 Centocor Inc Verfahren zur verbesserten herstellung von menschlichen antikörpern sowie hierzu benutzte zellen
ATE449853T1 (de) 1990-02-01 2009-12-15 Siemens Healthcare Diagnostics HERSTELLUNG UND VERWENDUNG VON GENBANKEN MENSCHLICHER ANTIKÖRPER(ßHUMAN-ANTIKÖRPER- BIBLIOTHEKENß)
US5811524A (en) * 1995-06-07 1998-09-22 Idec Pharmaceuticals Corporation Neutralizing high affinity human monoclonal antibodies specific to RSV F-protein and methods for their manufacture and therapeutic use thereof
US6399384B1 (en) * 1999-09-17 2002-06-04 Reneuron Limited Conditional immortalization of cells
FR2817875B1 (fr) 2000-12-07 2005-03-18 Technopharm Procede de preparation d'un anticorps monoclonal humain, de fragments de celui-ci ou d'anticorps comprenant de tels fragments, les anticorps ainsi obtenus et leur utilisation
AU2004215125B2 (en) * 2003-02-26 2011-01-06 Institute For Research In Biomedicine Monoclonal antibody production by EBV transformation of B cells
GB2398783A (en) * 2003-02-26 2004-09-01 Antonio Lanzavecchia A method for producing immortalised human B memory lymphocytes
DE602006021324D1 (de) * 2005-08-23 2011-05-26 Iq Corp Verfahren zur herstellung stabiler b-lymphozyten

Also Published As

Publication number Publication date
AU2006325236B2 (en) 2011-11-10
ZA200806094B (en) 2009-06-24
BRPI0619908A2 (pt) 2011-10-25
HK1127783A1 (en) 2009-10-09
ZA200904907B (en) 2010-04-28
CA2633601A1 (en) 2007-06-21
EP1974020B1 (de) 2011-06-15
AU2006325236A1 (en) 2007-06-21
ES2367322T3 (es) 2011-11-02
WO2007068758A1 (en) 2007-06-21
IL192095A0 (en) 2008-12-29
CN101374944B (zh) 2012-02-08
EP1974020A1 (de) 2008-10-01
NO20083160L (no) 2008-09-10
PT1974020E (pt) 2011-08-26
JP2013255515A (ja) 2013-12-26
KR20080097181A (ko) 2008-11-04
US8338172B2 (en) 2012-12-25
KR101508945B1 (ko) 2015-04-08
CN101374944A (zh) 2009-02-25
NZ569816A (en) 2011-10-28
US20090270268A1 (en) 2009-10-29
JP2009519026A (ja) 2009-05-14
DK1974020T3 (da) 2011-10-03
EA019505B1 (ru) 2014-04-30
EA200870062A1 (ru) 2009-04-28
CA2633601C (en) 2015-06-30
JP5431730B2 (ja) 2014-03-05
PL1974020T3 (pl) 2011-11-30

Similar Documents

Publication Publication Date Title
NO20083160L (no) Methods for obtaining immortalized anitbody secreting cells
US12351825B2 (en) Soluble antibody complexes for T cell or NK cell activation and expansion
Shi et al. More than one antibody of individual B cells revealed by single-cell immune profiling
Tsioris et al. Neutralizing antibodies against West Nile virus identified directly from human B cells by single-cell analysis and next generation sequencing
Cao et al. B. 1.1. 529 escapes the majority of SARS-CoV-2 neutralizing antibodies of diverse epitopes
Arumugakani et al. Early emergence of CD19-negative human antibody-secreting cells at the plasmablast to plasma cell transition
PH12020500160A1 (en) Reagents for expanding cells expressing recombinant receptors
IL287286B (en) Differentiated stem cell memory t cells, methods for their preparation and methods for using them
MX2018013008A (es) Anticuerpos st-2 humanos solubles y ensayos.
MY150553A (en) Heparin-binding epidermal growth factor-like growth factor antigen binding proteins
EA201000471A1 (ru) Антигенсвязывающие белки, способные связывать тимусный стромальный лимфопоэтин
MY162752A (en) Alpha-4-beta-7 heterodimer specific antagonist antibody
MX2013006428A (es) Proteinas de union a tnf-alfa.
MX2010007729A (es) Vectores de expresion de mamifero mejorados y uso de los mismos.
TW200626614A (en) Human monoclonal antibodies to influenza M2 protein and methods of making and using same
BR112021020426A2 (pt) Anticorpos anti-cd3 dependentes de ph projetados e métodos para sua geração e uso
WO2009035738A3 (en) Use of antibody secreting cell elispot to assess antibody responses following antigen exposure
AU2016204135A1 (en) Screening methods for transfusion related acute lung injury (TRALI)
WO2021226289A3 (en) Compositions and methods for tcr reprogramming using cd70 specific fusion proteins
Correa et al. Evaluation of antigen-conjugated fluorescent beads to identify antigen-specific B cells
WO2011050985A8 (en) Clonal expansion of b cells
BR112018014250A2 (pt) roedor, célula ou tecido isolados de roedor, célula imortalizada, célula-tronco embrionária de roedor, embrião de roedor, e, métodos para produção de um roedor e de um anticorpo
Vásquez et al. Rapid proliferation and differentiation of a subset of circulating IgM memory B cells to a CpG/cytokine stimulus in vitro
Liu et al. A rapid method to characterize mouse IgG antibodies and isolate native antigen binding IgG B cell hybridomas
Scholzen et al. Expansion of IgG+ B-cells during mitogen stimulation for memory B-cell ELISpot analysis is influenced by size and composition of the B-cell pool

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1974020

Country of ref document: EP